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!ABSTRACT 
Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, including 
Qatar. Hypertension is one of the most common CVDs that contribute to this mortality. 
Cadmium (Cd) is a well-known pollutant that has been suggested to be a risk factor for 
hypertension. However, the underlying mechanisms are still lacking. Very little is known 
about the effect of Cd on the expression of vascular alpha- 1 adrenoceptors (α1 ARs) in 
vascular smooth muscle cells (VSMCs). This study was therefore undertaken to 
determine the effect of Cd on the expression and sensitivity of vascular α1 ARs in vitro 
and in vivo. Along with that, there are several phenotypic changes could modulate the 
VSMCs function and contribute to CVDs including hypertension. These changes include 
hypertrophy, migration and senescence. The second objective of this study was to 
determine the effect of Cd on VSMCs phenotype. Human aortic smooth muscle cells 
(HASMCs) were incubated with different concentrations of cadmium chloride (CdCl2) 
for varying durations. The results indicated that Cd increases the expression of α1 ARs in 
HASMCs in a concentration and time dependent manner. To determine if Cd modulates 
the transcriptional activity of α1 ARs, cells were pre-incubated with actinomycin D, a 
DNA-dependent RNA synthesis inhibitor. Interestingly, the Cd-induced α1 ARs protein 
expression was abolished by actinomycin D. Moreover, this expression of α1 ARs was 
diminished when cells were pre-incubated with H89, a protein kinase A (PKA) inhibitor. 
This indicates that PKA plays an important role in mediating the Cd-induced
! expression of α1 ARs. α1 ARs activity was determined through functional study. Wistar 
rats were treated with CdCl2 at dose 15mg/kg/day via drinking water for 8 weeks. Blood 
pressure was measured at the baseline and after 30 days of treatment. Cd didn’t affect the 
vascular reactivity of rat mesenteric arteries in response to α1 ARs agonists, 
phenylephrine and norepinephrine (NE) as well as blood pressure. Antagonizing α1 ARs 
with prazosin didn’t show any response of other alpha’s AR.  To determine the effect of 
Cd on VSMCs phenotype, HASMCs were incubated with CdCl2. Our results showed that 
cadmium induces hypertrophy, migration and senescence. Taken together, our results 
dissect a novel pathway employed by Cd to increase expression (not the activity) of 
vascular α1 ARs, a major player in hypertension as well as VSMCs phenotypic 
modulation. This new paradigm offers a better understanding and thus potential 
amelioration of pollution-related CVDs.
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CHAPTER 1: INTRODUCTION 
Environmental pollution 
Environmental pollution is considered to be one of the critical concerns that has a 
significant impact on human health. Rapid growing, urbanization, industrial activities and 
abuse of available resources play a role in destroying and polluting the environment.   
These anthropogenic processes spread environmental pollutants everywhere: in air, soil 
and water. As such humans are becoming highly exposed to these pollutants, which may 
lead to the development of serious health problems. Recently, the World Health 
Organization (WHO) reported that 23% of the global disease burden is attributable to the 
environment (1). In fact around two million people died of complications that resulted 
from exposure to indoor air pollution, and the number of deaths resulting from diarrhea 
caused by the consumption of unsafe contaminated water reached 88% (1). In order to 
prevent or minimize the increment in these statistical data, a well-planed environmental 
management program is key to avoid illnesses caused by the abovementioned introduced 
environmental factors. It is estimated that implementing such a program and preventing 
or minimizing environmental pollution risk can actually save more than four million lives 
per year, the majority of which are in developing countries (1). 
Among the many factors that contribute to environmental pollution are heavy 
metals, which are characterized as having a density higher than 4.5 g/cm3 (2). Heavy 
metals can naturally be found within a range of background concentration in the 
environment; some examples of heavy metals include: lead, mercury, cadmium, arsenic, 
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chromium, zinc, nickel and copper. Anthropogenic activities can produce a higher 
concentration of these metals than the normal existing level. Such anthropogenic 
activities include plastic and rubber industries, metal smelting and refining industries, 
scrap metal, burning of elements-containing wastes and various consumer products (3). 
Therefore, changes of the concentration levels of these metals beyond the range of the 
background, increase the risk of environmental pollution, and unlike other types of 
pollutants, heavy metals are not easily removed from the environment and can persist in 
the environment for a very long time. Once released, heavy metals can travel to different 
environmental compartments and find their way to the food chain. Accordingly, the 
Protocol on Heavy Metals to the Convention on Long-Range Transboundary Air 
Pollution (CLRTAP) was adopted on 24 June 1998 in Aarhus (Denmark) to target three 
harmful metals, which are cadmium, lead and mercury. This protocol was amended in 
2012 to implement more strict regulations on heavy metals emissions (2).   
Cadmium   
Cadmium (Cd) is a naturally occurring heavy metal, which exist in the 
environment with a high toxicity. Cadmium has been listed as No 7 out of 275 most 
hazardous materials (ATSDR 2011) according to the Comprehensive Environmental 
Response, Compensation and liability (CERCLA) (4). Pure Cd is a soft, silver-white 
metal with a melting point of 320.9°C. Chemically it has the symbol Cd and atomic 
number 48. However, it is not easy to be found in nature as pure form, it is usually 
occurred in combination with other elements such as sulphur, which form cadmium 
sulphate, oxygen which form cadmium oxide and chlorine which form cadmium chloride 
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(5).  
 Cd can be released to the environment as a result of volcanic activities and 
industrial activities. Cd is widely used in industrial processes, e.g.: as an anticorrosive 
agent, as a stabilizer in polyvinyl chloride (PVC) products, as a colour pigment, a 
neutron-absorber in nuclear power plants, and in the fabrication of nickel-cadmium 
batteries as well as phosphate fertilizers which showed a big cadmium load (6). Cd can 
also be found in tobacco smoke (7). Cd level increased during the 20th century, one of the 
reasons is miscarry to get rid of Cd-containing products, this level started to decrease by 
the end of the 20th century due to stringent environmental legislation (8). In developing 
countries environmental Cd availability increased due to industrial processes and solid 
waste incineration (9). As a result, Cd particles reach soil and water through dry and wet 
decomposition. Once these particles settled down, they are taken up by plants and other 
organisms thus entering the food chain. In 1963 WHO international standard for drinking 
water recommended the allowable concentration of Cd intake to be 0.01 mg/litre (10). In 
1984 a new value was published in the first edition of the Guidelines for Drinking-water 
Quality, which was 0.005 mg/litre (10). This value was then decreased to reach 0.003 
mg/litre of water in the 1993 Guidelines based on the PTWI set by JECFA (10). All of 
these guidelines and regulations were established in order to reduce the availability of 
this toxic metal in water. The implementation of such straight regulations help to reduce 
Cd emissions in some developed countries (fig.1) (11). Cd concentration has been 
declined as shown in some developed countries, but the problem is that Cd exists in the 
environment with a high toxicity. It is toxic at very low exposure levels and has acute and 
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chronic effects on health and environment (12). The first documented incidence related to 
Cd toxicity was itai itai disease reported in Japan after the Second World War (13). This 
disease appeared to result from consumption of rice irrigated with Cd-contaminated 
water. Since then, increasing attention has been given to cadmium and its effects on 
human health.  
 
 
Human Exposure to!Cadmium 
Since Cd is spread in the environment, humans are highly exposed to this 
pollutant. It can enter the human body through different routes such as: gastrointestinal, 
pulmonary and dermal contact. The main source for the gastrointestinal exposure is Cd-
contaminated food. Once Cd reaches soil it persists for along time in which it is taken up 
Figure 18: Change of air concentrations of Cd at selected stations in Europe (CZ:Czech Republic, DE: Germany, 
GB: Great Britain, SK: Slovakia) from 1987 through 2005 (in ng m-3) (11). 
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by the plants and enter the food chain to target the human body. Cd-contaminated food 
can include animals such as goats, sheep, cows and chickens, which feed on the naturally 
contaminated sources. Also, seafood can be contaminated with Cd if they come from 
contaminated seas and oceans. The amounts of Cd ingested daily with food in most 
countries are in the range of 10 to 20 µg per day (7).  
Inhalation of Cd mostly affects workers in the industrial areas and people who are 
living near to those areas. Tobacco smoke contributes to inhalation exposure for smokers. 
Since one cigarette contains approximately 1 to 2 µg Cd, smoking one pack per day 
results in a daily uptake of Cd that approximates that derived from food (7). Workers who 
are working in the industrial areas can ingest Cd through contaminated hands. 
Dermal absorption occurs when the human skin get in contact directly with 
contaminated soil or water. Cd by this way penetrates the dermal cells to reach the blood. 
Two mechanisms facilitate cadmium absorption by the skin: binding of a free cadmium 
ion to sulfhydryl radicals of cysteine in epidermal keratins, or an induction and 
complexing with metallothionein (MT) (6). 
Cadmium metabolism 
Upon absorption, Cd ions cross various barriers and reach the bloodstream. There 
it binds to red blood cells or high molecular weight proteins such as albumin and 
metallothionein (MT) (14). Cd is transported through the blood stream and accumulated 
in body organs especially kidney and liver, with 50-80% of body burden being stored in 
kidney and liver (15). When cadmium reaches the liver it stimulates the production of 
MT, a protein that has a major role in Cd detoxification. MT then starts to bind to free Cd 
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to reduce toxicity. Cd complexes with MT then leaves the liver and arrives at the kidney 
to be cleared through glomerular filtration.  After filtration Cd is taken up by the 
proximal tubule where the bond between Cd and MT is cleaved and free Cd released. 
These free Cd start to induce the production of MT again in the kidney. MT production in 
the kidney is lower and inadequate to bind to free Cd. Free Cd then interacts with the 
kidney cells leading to kidney damage (15). Importantly, Cd has a very long biological 
half-life 15-30 years (16).  
Cardiovascular Diseases 
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and 
mortality in developing and developed countries (17) .In 2004 alone, around 17.1 million 
people died because of CVDs. This number is estimated to increase and reach around 
23.6 million by 2030 (18).  
Hypertension is one of the CVDs that is considered an endemic problem (19). In 
fact, hypertension remains the most powerful risk factor for CVDs (20). It is the most 
chronic disease that affects one billion of human population worldwide (21). 
Hypertension and hypercholesterolemia are responsible for around 50-75% of all CVDs 
(18). The American Heart Association redefined hypertensive to be pre-hypertension 
when the blood pressure reaches 120 to 139 mmHg over 80 to 89 mmHg, and 
hypertension when blood pressure is 140 mmHg over 90 mmHg or above (22). Several 
risk factors are associated with hypertension including smoking, diet, lifestyle, genetic 
factors and physical inactivity. In addition to these factors, environmental pollution 
contributes in inducing hypertension. Recently, increasing evidence-highlighted cadmium 
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to be one of these contributors. Epidemiological studies found that there is a correlation 
between blood level of cadmium and blood pressure elevation (16). More supportive 
evidence showed that animal treated with CdCl2 also modulate blood pressure and induce 
hypertension (23) (24) (25). 
The regulation of blood pressure is subject to various regulatory influences. 
Indeed, many regulators are integrated, so that a blood pressure homeostasis is 
maintained. These includes: the vasculature, kidneys, sympathetic and central nervous 
system as well as their hormonal regulators (26). Hormonal regulation requires 
interaction between the hormones and specific receptor that are mostly distributed on the 
cell membranes. These hormones are the active substance that promote cell-signaling 
cascade when they bind to its receptor. In pharmacology, these receptors are the target for 
therapeutic agents. One of the most important receptors that contribute to the generation 
of vascular tone is adrenergic receptor 
Adrenergic receptors are a G-protein coupled transmembrane receptors (GPCRs) 
that are divided into three families: α1 (α1A, α1B, α1D), α2 (α2A, α2B, α2C) and β 
(β1, β2, β3) (27). These receptors are sensitive to catecholamines: epinephrine (EP) and 
norepinephrine (NE). Each type and class of these receptors is responsible for specific 
function based on its location and distribution among body tissues (Table.1) (28).  
Table 1: Distribution and Response of Adrenergic Receptor Subtypes (28).  
Receptor Physiology 
Tissue Response 
α1A,B,D Smooth muscle: vascular, iris, radial 
ureter, pilomotor, uterus, sphincters 
Contraction 
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(gut, bladder) 
Smooth muscle (gut) 
 
Relaxation 
 
Heart Positive inotropic (β1 >> α1), cell 
growth, hypertrophy 
Salivary gland 
 
Secretion 
 Adipose tissue 
 
Glycogenolysis 
 Sweat glands 
 
Secretion 
 
 Kidney (proximal tubule) Gluconeogenesis, Na+ reabsorption 
α2A,B,C Presynaptic autoreceptor on 
sympathetic nerve endings 
 
Inhibition of norepinephrine release 
 
Platelets 
 
Aggregation, granule release 
 
Endocrine pancreas 
 
Inhibition of insulin release 
 
Adipose tissue 
 
Inhibition of lipolysis 
 
Vascular smooth tissue 
 
Contraction 
 
Kidney 
 
Inhibition of renin release 
β1 Heart  
 
Positive inotropic effect, positive 
chronotropic effect, cell growth, 
hypertrophy 
 
Adipose tissue Lipolysis 
 
Kidney Renin release 
β2 Liver 
 
 
Glycogenolysis, gluconeogenesis 
 
Skeletal muscle  
 
Glycogenolysis, lactate release 
 
Smooth muscle: bronchi, uterus, gut, 
vascular (skeletal muscle), detrusor 
Relaxation 
 
β3 Endocrine pancreas 
 
Insulin secretion  
 
Salivary gland Amylase secretion 
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Adipose tissue 
 
Lipolysis 
 
Striated muscle Thermogenesis 
Alpha 1 Adrenergic Receptors (α1 ARs) 
α1 ARs are the most involved type in smooth muscle cells contraction. These 
receptors are highly expressed in the vascular smooth muscle cells (VSMCs) and are 
responsible of VSMCs contraction. Due to this, α1 ARs have an important role in the 
vasculature. Adrenergic receptor-induced contraction requires an interaction between the 
receptor and EP or NE. This interaction activates the receptor to undergo signaling 
transduction. Upon activation, Gq/11 protein dissociates to stimulate phospholipase C 
causing increase in Inositol triphosphate (IP3) and release calcium ions (Ca2+). This leads 
to activation of protein kinase C and end with VSMC contraction  (Fig.2). 
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The physiological function of α1 AR varies according to its expression in various 
tissues and organs. It has a different role in several locations among body tissues and 
organs as shown in table.2: 
Table 2: Physiologic Function of α1 AR (27).  
Organ Physiologic response Subtype 
Heart: Myocardium Inotrophy α1a, α1b 
 
Hypertrophy  α1a 
 
Pre-conditioning α1a 
 
Conduction system Arrhythmias, bradycardia ? 
Brain Alertness ? 
Vessels Contraction (artery and vein) α1a>α1b>α1d 
Figure 2: Activation of α1 AR and intracellular signaling cascade. 
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Prostate Prostate smooth muscle tone α1a 
 
Bladder (detrusor) Irritability α1d 
 
Gut, gall bladder Contraction ? 
Regulators of α1 AR activity 
In the normal condition, the concentration level of circulating EP and NE is 
highly controlled in order to maintain homeostasis. Two important mechanisms are 
involved; one of them is enzymatic degradation by Catechol-O-methyltransferase enzyme 
(COMT). This enzyme acts to inactivate the excess of catecholamines such as Dopamine, 
EP and NE. The second pathway is the presence of presynaptic α2 AR at the nerve ends. 
When there is overload of NE secretion, NE binds to the receptor to inhibit the release of 
this hormone. Therefore, any abnormality in these two mechanisms will cause a 
disruption in the vascular tone, where high or low blood pressure is expected. 
Characteristics of VSMCs Phenotypic Modulation 
VSMCs form the medial layer of the blood vessels that support the vasculature. 
Interestingly, these cells are contract in response to stimulator to control the blood flow 
and pressure. Indeed, in normal physiological condition most of VSMCs in the vascular 
wall characterized by spindle-shape, high contractility and low proliferation rate 
(contractile phenotype) (29). However, in response to injury the contractile phenotype of 
VSMCs is switched to a synthetic phenotype via a process called phenotypic modulation. 
Phenotypic modulation is a process in which VSMCs loss their contraction property and 
characterized by a decrease in SMC differentiation marker gene expression and elevation 
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in proliferation, migration and matrix synthesis (30). VSMCs phenotypic modulation may 
be induced by numerous environmental stimuli such as growth factors, inflammatory 
mediators, mitogens and mechanical influences (31). Under these circumstances, VSMCs 
remodeling contribute to the development of CVDs such as atherosclerosis, restenosis, 
aneurysm as well as hypertension (32).    
Beside AR-induced hypertension, phenotypic modulation has a role in disrupting 
the vascular tone and progression of blood pressure. For example, changes in VSMCs 
phenotype could alter the wall to lumen ratio, decreasing inner diameter and causing 
blood pressure resistant (Fig.3). Our study highlighted hypertrophy, migration, 
senescence and viability as examples of VSMCs phenotypic modulations that could 
affect the blood pressure. 
 
 
 
 
 
 
            
 
 
Figure 3: Representative comparison of lumen diameter between normal vessel (a) and vessel after phenotypic 
modulation (b). 
               
!
Lumen Lumen 
Wall Wall 
(a) (b) 
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VSMCs hypertrophy is a process results in increase in VSMCs mass within the 
blood vessels. Cell enlargement occurs due to a consequence of events and mechanisms. 
These events include increase in intracellular protein synthesis and decrease in protein 
degradation. Increase water content may also cause an increase in cell volume due to 
disruption in water and ion exchange. In addition to these two mechanisms, DNA 
synthesis also could lead to cell hypertrophy. The increase in the cell volume leads to 
increase in the wall/lumen ration (decrease lumen diameter). This phenomenon could be 
initiated due to several factors such as growth factors, reactive oxygen species and G-
coupled protein receptors (GPCRs) agonist. 
During the phenotypic modulation, migration and proliferation are common. 
Migration is a normal physiologic process occurs during the vascular development and 
vascular repair in injured tissues. It is the movement of the cells from adventitia to the 
intimal layer and the formation of neointima. Once migrated cells reach that site they 
start to proliferate as a sequence of repair process. Proliferation of VSMCs is considered 
a central event of the repair process (33). The movement and proliferation of VSMCs are 
initiated primarily via growth factors that activate cell surface receptors (34). Upon 
activation, VSMCs undergo a sequence of signaling transduction to promote cell 
migration and proliferation. At this stage cells reduced the expression of proteins that are 
responsible for contractility (35). Hence, VSMCs works to control vascular repair instead 
of vascular contraction. Pathologically, these processes are well-known in atherosclerosis 
that contribute in the formation of atherosclerotic plaque (36). Atherosclerotic plaque and 
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the formation of the neointima modulate the vascular wall causing lumen narrowing 
(fig.4).  
 
Figure 4: Illustration of lumen diameter in normal condition (a) and after the formation of neointima characterized by 
migratory and senescent cell (b). 
 
Vascular senescence is another type of phenotypic modulation that is commonly 
found in the neointima (Fig.4). Vascular senescence is characterized by a permanent cell 
cycle arrest involving cellular and gene expression changes (37). This phenotype of 
VSMCs is normally found in aged arteries; hence it is a mark for mammalian aging (37). 
Moreover, senescent cells are one of the key players in the pathogenesis of 
atherosclerosis (38). It can be characterized by increased NADPH oxidase activity, high 
production of reactive oxygen species, low catalase, high expression of cell cycle 
! Lumen 
Wall 
!
! ! ! !! !! !
!! !
Wall 
Lumen 
Migratory)cell 
Senescent'cell 
(a) (b) 
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progression regulator proteins at stage G1 (p21 and p53) and increase in β-galactosidase 
activity (39).  
 !
     
 
 
 
 
 
 
 
 
 !  
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LITERATURE REVIEW 
Cadmium (Cd) is a natural element of the earth crust that attributes to 
environmental pollution. As mentioned earlier, several guidelines were established in 
order to control the spread of this toxic contaminant. The latest update on these 
guidelines was established by WHO to be 0.003 mg/liter as a safe water daily intake level 
for human. The toxic effect of Cd is varied among species. In rats and mice for example, 
the lethal acute oral dose (LD50) is between 60 to 5000 mg/kg body weight (15). While in 
humans it ranges between 350-3500 mg of Cd (40). Route of exposure are varied, but the 
most serious significant one is through dietary intake (41) as well as smoking (42). 
Smokers receive the double daily dose of Cd compared to non-smokers due to smoking 
behavior (41).  
In human, food is the main source of Cd exposure through consumption of food, 
such as vegetables and grains that are grown in contaminated areas, or seafood originated 
from contaminated seas and oceans. Table. 3 summaries Cd level in a list of food and 
estimated exposure rate (43). 
Table 3: Cd levels in food and estimates of dietary Cd exposure (adapted from Galal-Gorchev, 1993; Rayment, 1995; 
Food and Agriculture Organization/World Health Organization, 1998; Resources Sciences, 1997; Australia New 
Zealand Food Authority, 1998) (43).  
 Cd level (mg/kg) 
Food item Maximum Typical Intake level 
(g/d) 
Extreme 
exposure 
(µg/d) 
 
Typical 
exposure 
(µg/d) 
Vegetables, including 0.1 0.05 250 25 12.5 
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potatoes 
 
Cereals, pulses and 
legume, including rice 
and wheat grain 
0.2 0.05 200 40 10 
Fruit 0.05 0.01 150 7.5 1.5 
Oilseeds and cocoa 
beans 
1 0.5 1 1 0.5 
Meat of cattle, poultry, 
pigs and sheep 
0.1 0.02 150 15 3 
Liver of cattle, poultry, 
pigs and sheep 
0.5 0.1 5 2.5 0.5 
Kidney of cattle, 
poultry, pigs and sheep ! 
2 0.5 1 2 0.5 
Fish 0.05 0.02 30 1.5 0.6 
Crustaceans, molluscs 2 0.25 3 6 0.75 
Total    93.5 30 
 
Qatar is one of the countries that depends on marine life for food consumption 
due to its location, where the sea is surround it from 3 sides. As Qatar encounters huge 
industrial activities during the last five years, it is expected that Cd deposition 
contaminate marine life. Because the two main industrial areas in Qatar are located in the 
coast, this may lead to the contamination of seawater. Consequently local fish and shrimp 
may accumulate the Cd in their body and reached the human body through the food chain 
and consumption of contaminated seafood. Few studies were carried out to examine the 
bioaccumulation of trace metals (including Cd) in marine organisms around Qatar and the 
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region. In 1991, results showed a significant increase in Cd concentration in Qatari fish 
and other marine organisms (44). El Sayed M & Dorgham M., conducted a study on 
different species of Macroalgae from the Qatari Coastal Water and they found a high 
concentration of iron and Cd in some species (45). Recent study aimed to detect the 
concentration of heavy metals in soft tissue of oyster (Saccostrea cucullata) collected 
from the Lengeh Port coast, Persian Gulf and Iran. Results showed that soft tissue of 
oyster (Saccostrea cucullata) accumulates high Cd concentration, which exceed the 
permissible limit for human consumption (46).  
The gastrointestinal (GI) absorption of cadmium was estimated to be around 5% 
of the ingested amount, where the daily excretion rate reached 0.005% of the body 
burden (10). Body health status could affect the absorption rate of Cd. In iron-deficient 
people, the percentage of absorbed Cd can reach 15-20% (40). Cd interferes with iron 
absorption leading to anemia. In this case; duodenal iron transporter were suggested to be 
up regulated and increase Cd absorption in the intestine (47). This evidence is highly 
correlated to what was reported by Donpunha et al., they found that there is no 
interference with iron absorption when the Cd-fed mice is supplemented with iron (48). 
Supplementation with iron and other nutritious elements is significant way to reduce Cd 
toxicity.  
Once Cd is absorbed and enters the circulation it binds to Metallothioneins  (MT), 
which acts as the body’s defensive mechanism to reduce Cd toxicity as mentioned earlier. 
Due to its low excretion rate, Cd circulates in the blood binds to MT and accumulates 
mainly in liver, kidneys and testes due to their high ability to produce this protein (47). 
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Indeed, MT is overexpressed in Cd-induced liver toxicity at mice model (49).  
Cadmium and Health Effects 
Several acute and chronic health effects result from Cd intake based on the 
consumption rate. Low Cd chronic exposure seems to be one of the great challenges of 
the 21st century due to its long term health effects (50). After long period of Cd exposure, 
it accumulates in the body and causes multi-systematic problems. The most affected 
organs are kidneys and the liver. Cd reaches the kidney in the form of cadmium-
metalothionine (Cd-MT). This complex is filtered through the glomerulus, and then 
reabsorbed by the proximal tubulus after break down of Cd-MT. Cd remains in the 
tubular cells causing tubular dysfunction and kidney damage. Cd-induced kidney damage 
is recognized by urinary excretion of low-molecular-weight proteins such as β2-
microglobulin, N-acetyl-α-D-glucosaminidase (NAG), and retinol-binding-protein (RBP) 
(51). 
The outbreak of Itai Itai disease in Japan in the 1940s illustrates the association 
between Cd toxicity and skeletal system. In China, similar case was reported with 
population who lived near to a smelter and used the contaminated river water with the 
smelter waste discharge for irrigation of their fields (52). People in this situation showed 
a decrease in the bone density due to low mineralization, increase in osteoporosis and 
increase in bone fracture rate (14). Similar evidences of increased skeletal fragility and 
decreased mineral density were reported from animal study in which rats were fed for 
long-term on dietary Cd at levels corresponding to environmental human exposure (53). 
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Accumulative evidences suggested that Cd could be a risk factor for cancer. 
International Agency for Research on Cancer (IARC) classified Cd as human carcinogen 
(54). Different cancer cases were resulted from Cd exposure such as kidney, lungs, 
prostate, breast and endometrial cancers in females (55). Cd mimics sex hormones by 
activating estrogen and androgen receptors and leads to the development of breast and 
prostate cancer (56). A range of underlying molecular mechanisms has been addressed to 
initiate cancer. These mechanisms include DNA damage, reactive oxygen species (ROS) 
production and the consequences of ROS signaling (57).  
Body burden result from Cd toxicity might be due to the activation of oxidative 
stress pathway. Oxidative stress is a response of biological system that disturb the redox 
balance at the cellular level and result in macromolecules damage such as protein 
degradation, cross-links in DNA and membrane fatty acid peroxidation (58). 
Accordingly, Cd has shown to induce oxidative stress and inhibit the antioxidant 
enzymes (59). Moreover, it induces the formation of free radicals and ROS that has an 
effective role in tissue damages (60). 
Cadmium and Hypertension 
In the last few decades, Cd has been considered as a risk factor for CVDs 
including hypertension. Since that time researchers start to investigate the relationship 
between Cd and CVDs particularly hypertension.  Epidemiological studies revealed the 
presence of Cd in urine is correlated with the elevation of systolic and diastolic blood 
pressure (61). In the United States (U.S) general population, Cd has been observed to 
increase the prevalence of peripheral arterial disease, all participant Cd level was below 
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the safety standard for Cd (5µg/L) (62). This relationship was also addressed by other 
epidemiological studies in which Cd corresponded to the prevalence of stroke and heart 
failure (63). The Korean National Health and Nutrition carried out an Examination 
Survey for two years (2008–2010) on Korean population over 20 years old. The result of 
this study showed a significant association between blood Cd and hypertension in women 
and men (64). Urinary and serum level of Cd has been associated with cardiovascular and 
cerebrovascular disease (65). A study was conducted on peoples with high urinary Cd 
levels (≥ 5 µg/g creatinine) and followed up for chronic Cd toxicity such as hypertension. 
Results showed urine Cd level is attributed with elevation in blood pressure (66). Urine 
Cd level showed to be higher in hypertensive cats compared to normotensive ones in a 
cross-sectional study (67). Recently, a demonstration from population study showed an 
association between blood and urine Cd level with the prevalence of peripheral artery 
disease among 489 participants (68).  
Beside epidemiological studies, In vivo studies considered as an important field to 
demonstrate the relationship between Cd toxicity and blood pressure. A large number of 
animal studies were conducted using different species with different ways of 
administration to illustrate this phenomenon. The first study was published by Schroder 
addressed in 1962 and showed that chronic exposure of low Cd level induce hypertension 
in rats (69). Similar findings were also addressed by Perry and Erlanger suggested that 
non-toxic pressor doses of Cd (0.1 to 5 ppm) are able to modulate blood pressure (70). Cd 
produced hypertension in hypertension sensitive rats when they receive 1-5 mg Cd/L via 
drinking water, and it was suggested that genetic differences influence Cd-induced 
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hypertension (71). Significant increase in blood pressure were observed in female Long-
Evans rats exposed to 0.1, 0.25, or 0.5 ppm of Cd via drinking water for 6 to 18 months 
(72).  Albino rats received 15µg/ml Cd for 30 days showed an obvious increment in 
blood pressure, where systolic and diastolic blood pressures rose from 102.8 +/- 7.0 and 
81.2 +/- 3.8 mm Hg to 128.1 +/- 4.6 and 107.9 +/- 7.4 mm Hg (73).  Recently, evidence 
was reported that Cd modulates hypertension. A study conducted by Donpunha et al. 
showed a significant increase in the systolic, diastolic blood pressure and the mean 
arterial blood pressure of mice treated with 100 mg/l CdCl2 via drinking water for 8 
weeks (24). These evidence support that Cd could be a risk factor for hypertension. 
Blood vessel is a hollow tube that consist of two main layers, the endothelial cells 
(ECs) which are a line of cells that cover the entire blood vessels and form as a 
connection bed between blood and the body tissues (74). This connection ensures the 
delivery of oxygen and nutrients to the cells for survival. Beneath the ECs is a thick layer 
of VSMCs. VSMCs is the muscular part of the vessel that is responsible for its 
contraction. Once Cd enters human body, it reaches the blood stream and targets the 
vascular wall (47). Changes in the ECs, vascular receptors expression and contractility 
level are well-known factors to elevate blood pressure. Evidence suggested that Cd could 
target blood vessels and result in blood pressure modulation. Cd can potentiate 
cytotoxicity of the cells in the vessel wall. Cd showed a cytotoxic effects to ECs by 
destroying the monolayer of ECs (75). These finding could be related to the effect of Cd 
on VE-cadherin (cell adhesion molecules) that has a major role in connecting the cells 
together as reported by Prozialeck et al. (76). They found that 10 and 100nM cadmium 
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decrease the cell contacts through the monolayer of HUVEC cells. Disruption of ECs 
contacts leads to the alteration in the structure of vascular endothelium. Other process 
that might affect endothelial integrity is the induction of cell death. It has been shown that 
ECs are targeted by Cd and end with cells death (77). It has been shown that Cd induce 
cell apoptosis through the p38 MAPK dependent mechanism in brain microvascular ECs 
(78). Cd-induced-endothelial cell death revealed to be due DNA strand damage and p53 
downstream activation (79). Cd showed to inhibit the migration, proliferation and tube 
formation of HUVECs when they exposed to 1.0 µM-1.0 mM of CdCl2 (80). Similar 
findings were revealed recently and suggested that Cd inhibit the endothelial migration 
and tube formation at dose 5µM of CdCl2 (81). These processes are key players and have 
an important role in angiogenesis. Consequently, Cd has a direct effect on angiogenesis 
and tube formation, but this effect showed to be dual effect. Vascular endothelial growth 
factor (VEGF)-dependent mechanism of angiogenesis was tested on ECs (HUVECs) 
treated with different concentration of CdCl2 (2.5-40 µM). Low Cd concentration showed 
to increase the secretion of VEGF and induce the tube formation in HUVECs. Unlike low 
concentration, high Cd concentration showed an adverse effect and inhibits the tube 
formation (82). Therefore, any damage in the endothelium will alter its permeability (77), 
and result in the formation of gaps between the cells. Gaps formed between the 
endothelial cells, helps Cd to transfer from blood stream to the medial layer (76).  
When Cd damages the unique layer of ECs it reaches the VSMCs, which works as 
a recipient for Cd toxicity. Kaji T et al. found that vascular smooth muscle cells exhibited 
high sensitivity to Cd toxicity compared to Chang-liver cells. High sensitivity of VSMCs 
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(without any species-related differences) suggested to be due to accumulation of such 
metal inside the cells (83). Consistent with these findings, Cd showed to accumulates in 
the medial layer of smokers aorta compared to intima and adventitia (84). Cd could affect 
the viability of VSMCs and lead to cellular dysfunction. VSMCs viability decreased in a 
concentration dependent-manner (85). In the same study, CdCl2 also showed to increase 
ERK 1 & 2 in a biphasic manner. This increment reached the maximum when 
Spontaneously Hypertensive Rat (SHR) VSMCs exposed to 1 and 4 µM. On the other 
hand, a reduction was revealed with Wistar Kyoto rat (WKY) cells at 2µM. It has been 
indicated also that CdCl2 elevated PKC expression in both cell types, where the highest 
elevation was observed in SHR VSMCs (85). Moreover, adverse effects may initiated 
due to VSMCs Cd toxicity, Mikhaleva et al. investigated that chronic oral administration 
of 2.5 mg/100 g body weight CdCl2 to albino rat might cause hypertrophy in the left 
ventricular cardiomocytes as well as arterial walls (86). Interestingly, more complications 
could occur due to endothelial dysfunction that trigger different factors associate in the 
pathology of the vascular wall. These findings are supported by other study, Park SL et al 
reported that Cd induces the expression of adhesion molecules such as (ICAM-1) and 
(VCAM-1) which facilitate the migration of immune cells through the vessel wall (87). 
Infiltration of immune cells helps them to reach the intimal layer and start to secrete 
inflammatory signals as a sign of inflammatory response to injury. Consentient with these 
findings, leukocytes number was significantly increase in Cd-treated mice causing a 
systematic inflammation as consequences of Cd toxicity (88). An interesting review done 
by Olszowski et al. suggested that micro molar concentration of Cd result in up-
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regulation of inflammatory mediators in different studies (in vivo and in vitro). Increase 
in IL-6 was revealed in human fibroblast and other cell lines treated with Cd (89). 
Moreover, TNF-α level in plasma was also increased in response to Cd administration in 
rats (90). IL-6, TNF-α and other cytokines have a critical role in disrupting the vascular 
wall (91). These evidences could be linked directly to the effect of Cd on the secretion of 
inflammatory mediators and induce inflammatory response. 
Inflammatory response stimulates VSMCs migration and proliferation to 
contribute in the formation of atheroma in the intima. It has been suggested that low level 
of Cd (100nM or less) may enhance the proliferation of vascular smooth muscle cells 
through intracellular calcium-dependent signaling pathway (92). Migration could 
enhance by the matrix metalloproteinases (MMPs). MMPs facilitate migration by 
catalyze and removal of the basement membrane that surround VSMCs (34).  It has been 
shown that MMPs are elevated in rat treated with Cd as reported by Kirschvink et al. 
(93). In addition, findings were summarized by Newby A. C. suggested that MMPs 
activation increase and induce VSMCs migration (34). Based on these data, VSMCs 
could be migrated due to Cd toxicity as a key element in vascular pathogenesis.   
Cd could also affect the vascular wall by modulating the molecular pathways that 
control the blood pressure. For example; Nitric oxide (NO) is a signaling molecule that 
regulates high blood pressure and mediates vascular homeostasis (94). NO is synthesized 
by NO synthase (NOS) proteins. NOS are constitutively expressed such as neuronal NOS 
(nNOS) and endothelial NOS (eNOS). Other NOS form can be regulated by the 
stimulation of cytokines and called inducible NOS (iNOS). The reduction in NO 
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production mediates blood pressure and cause hypertension. This reduction can be 
achieved by modulating the NO bioavailability or through NOS expression. A reduction 
in eNOS protein level was observed in rat treated with Cd at doses 10 and 50 ppm (95). 
Other mechanism was addressed by Majumder et al. in which Cd inhibits eNOS 
phosphorylation (96). In contrast, conflicting data were published by Takahashi et al., 
which revealed that in vitro Cd treatment of aortic strips significantly up-regulated the 
expression of iNOS and eNOS (97). Overexpression of eNOS was also showed recently 
in rats intoxicated with low chronic CdCl2 (100mg/L), accompanied with a decrease in 
NO bioavailability (50). Moreover, NO bioavailability is another angle that can be 
addressed as pathway of Cd-induced hypertension. NO formation was decreased in rat 
received acute i.c.v (intracerebroventricular) Cd injection (98). Administration of 50 or 
200 ppm CdCl2 via drinking water showed a decrease in serum NO concentration (99). 
This could be liked to the initiation of oxidative stress, one of the main endogenous 
actions that triggered by Cd toxicity as mentioned earlier. Vascular oxidative stress 
indicated a decrease in NO production (100). Therefore, any alteration in the NO 
production affects blood pressure.  
Studies were applied to investigate the activity of the vascular wall in response to 
several agonist and antagonist that has a role in initiating the vascular tone. Blood vessel 
contractility is initiated by several mechanisms one of them are EP or NE hormones. 
These hormones are known to target adrenergic receptor expressed in VSMCs to induce 
contraction. The concentration of these hormones is regulated by Catechol-O-
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methyltransferase enzyme (COMT). This enzyme showed to be inactivated due to Cd 
toxicity (101). 
Vasoconstriction responsiveness to Cd on isolated blood vessels was investigated 
in order to clarify the relationship between Cd and hypertension.  Cd showed to have 
several actions on the neurohumoral mechanisms that mediate the vasculature function 
(102). In 1978, Nechay et al. found that Cd can act differently on the vascular bed based 
on the exposure level. High pressor response to NE was observed when rat injected with 
low Cd dose (1-2.25mg/kg) compared to high dose (7.5 mg/kg) (103). Cd showed a dual 
effect on isolated rat thoracic aorta treated with a serial concentration of Cd (10-9 – 10-4 
g/ml). Low doses showed to induce vessel contraction while the high doses induce 
relaxation (104). The sensitivity of the vascular bed to NE and the perfusion pressure 
were elevated in CdCl2-induced hypertensive rats (105). Similarly, exogenous NE 
potentiate the vasoconstriction of mesenteric artery isolated from rat received cadmium 
chloride intragastrically (20 mg/kg body weight/week), where the 50% effective doses 
(ED50) showed to be lower in Cd-poisoned rats (106). These results could be linked to the 
increase in the sensitivity of postsynaptic alpha-adrenergic receptor to NE. In response to 
phenylephrine and acetylcholine, vasoconstriction and vasodilation were augmented 
when aortic strips were incubated with 10µM CdCl2 (97). The contractile response to 
phenylephrine (alpha 1 AR agonist) was increased in the aorta of Cd-treated rat 
(100mg/L via drinking water) (50). In term of vascular relaxation, Cd showed to suppress 
vascular muscarinic receptor sensitivity to acetylcholine in isolated rat aorta. The 
sensitivity was significantly decreased at 10 and 50 ppm Cd exposure (25). Gokalp et al 
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2009 noticed that relaxation responses were reduced in thoracic aorta of Cd-hypertensive 
rat (intraperitoneal administration 1mg/kg/day for 15 days), and they suggested that, this 
observation may be related to the inhibition of NO production and endothelial damage 
(107).  
Hypothesis and study objectives 
Vasoconstriction of the blood vessels has a critical role in evoking blood pressure. 
Several mechanisms were investigated, but still few available data showing how Cd-
induce hypertension. Among all hypertension pathways, in this study we focused on the 
alpha 1 adrenergic receptor pathway because it has been poorly investigated. From the 
available evidence, we found that Cd inhibits the function of Catechol-O-
methyltransferase enzyme (COMT) which regulates epinephrine and norepinephrine. 
Consequently, the vascular reactivity showed to be augmented in response to 
norepinephrine and phenylephrine as an agonist of α1! AR. Based on these previous 
findings and what is known to us, the direct effect of Cd on the α1!AR!receptor is poorly 
investigated. This led us to hypothesize that cadmium increases expression and/or 
activation of vascular α1#AR. Moreover, the literature showed that Cd has an effect on 
the on the function and morphology of vascular wall cells, which leads to vascular 
dysfunction. Little is known about the effect of Cd on VSMCs phenotypic modulation as 
an indirect mechanism of blood pressure elevation. Thus, another hypothesis was stated 
that cadmium induces the phenotypic modulation of vascular smooth muscle cells.  
In order to fill the gaps in literature and to dissect new role on how Cd-induce 
hypertension, we aimed in this study to: 
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1) Determine the effect of cadmium on the expression and activation of vascular α1 
adrenergic receptors.  
2) Determine the effect of cadmium on VSMCs phenotype. 
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CHAPTER 2: RESEARCH METHODOLOGY 
#
1) Cell Culture: 
Human aortic vascular smooth muscle cells (HASMCs) (Cell Applications INC; 
U.S), were grown in Dulbecco's Modified Eagle Medium (DMEM) (Gibco; U.S; cat# 
31885049) mixed equally (50:50) with F-12 media (Gibco; U.S; cat# 21765037). 
DMED/F-12 mixture was supplemented with 10% FBS, 1% Glutamine and 1% 
Antibiotic-Antimycotic cocktail (Gibco; U.S; cat# 15240062). Cells were incubated at 
37°C in a humidified chamber in an atmosphere of 5% CO2. Cells were used at passages 
between 9 and 12. Before treatment, cells were made quiescent by serum starvation 
(0.5% FBS-containing media) for 24 hours.  
2) Western Blotting: 
Cells were harvested into a lysis buffer (60mM Tris pH 6.8 and 2% SDS). Cells 
were scraped, sonicated for 5 to 10 seconds and then centrifuged at 10,000g for 15 min at 
4°C.  The supernatant was then quantified for protein concentration (BCA, Thermo 
Scientific, U.S , Cat#23227) and stored at -80°C.  
Equal protein samples were mixed with 5X sample buffer (4% sodium dodecyl 
sulfate (SDS), 20% glycerol, 0.5M Tris pH 6.8, 10% β-Mercaptoethanol and 0.10% 
Bromphenol blue) and loaded onto 10% SDS-polyacrylamide gel. Then the migrated 
proteins were transferred to a PVDF membrane at 100V for 1 hour. The membrane was 
washed 2 times for 5minutes each with Tris-buffered saline and Tween20 (TBST) 
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(0.02M Tris, 0.15M NaCl and 0.1% Tween) and blocked in 5% non-fat milk in TBST. 
The blocking was performed for overnight at 4°C on rocking plate. In the next day the 
membrane was washed three times with TBST for 5 min each. After that, the membrane 
was incubated with rabbit monoclonal primary antibody against α1 AR!(1:1000 dilution in 
TBST) (Abcam; UK; Cat# ab137123) for 1hr. After incubation, the membrane was 
washed 3times for 10mins each. Then membrane was incubated with Goat polyclonal 
secondary antibody (abcam; UK; Cat# ab97051) 1:5000 dilution in 5% non-fat milk-
TBST for 1hr. After that, the membrane was washed 3times/15mins. Bands were detected 
using enhanced chemiluminescence and quantified.  Three independent experiments were 
performed for each treatment. 
The same membranes were stripped following harsh stripping protocol from 
abcam*. Reprobing was done by applying Glyceraldehyde 3-Phosphate Dehydrogenase 
antibody (GAPDH) as a loading control. GAPDH bands were used for Western blot 
normalization. 
*Harsh stripping: 
Stripping buffer (20 ml SDS 10%, 12.5 ml Tris HCl pH 6.8 0.5M, 67.5 ml ultra 
pure water, 0.8 ml β-mercaptoethanol) was warmed to 50°C. Membranes were covered 
with enough stripping buffer in a tight plastic box (j50°C up to 45 min with some 
agitation). After disposing of the stripping buffer, the membrane was placed under 
running water for 1 hr. Then it was washed extensively with TBST for 5min to remove β-
mercaptoethanol traces. After following all these steps, the membrane is blocked and the 
above western protocol was continued. 
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3) Migration Assays: 
Chemotaxis chamber:  
24-multiwell insert system (8 um pore size, polyethylene terephthalate (PET) 
membrane) was used for this experiment. 10,000 cells were seeded with serum free 
media in the insert of the chamber. Complete media (10% FBS, 1% Glutamine and 1% 
Antibiotic/Antimycotic cocktail) was added to the lower chamber to serve as!chemotactic 
factor. Treatment was applied directly after seeding: control, 10 nM, 1000 nM and left for 
24 hrs at 37°C in a humidified chamber with an atmosphere of 5% CO2..!  24 hrs. post-
treatment, media was aspirated and cells were washed 2 times with PBS. Fixation 
solution (4% formaldehyde in PBS) was added for 10 min. The fixative was then 
aspirated and the inserts washed 2 times with PBS, incubated with 100% methanol for 20 
min, then washed 2 times with PBS. Staining (1% crystal violet) was applied for 5 min 
followed by washing with PBS. Non-migrated cells were removed by sterile cotton swap. 
Photos were taken from at least 5 random fields by an!inverted contrast phase microscope 
(IX71 Olympus) to count the number of migrated cells. 
Wound healing: 
40,000 VSMCs cells were seeded in 6-well culture plate and left till reached 
confluence. They were then serum-starved for 24 hrs. A scratch/wound was created in the 
center of monolayer by using 200µl tip. Treatment (10 and 1000nM) was added directly 
after wound creation. Wound healing was observed and photomicrographs were taken 
every 2 hrs.    
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4) Senescence-associated beta-galactosidase (SA-gal) activity: 
Cells were seeded in 6-well plate until they become sub-confluent and serum-starved 
for 24 hrs. Treatment was applied for 48 hrs as the following: control, 10 nM and 1000 
nM. 48 hrs post-treatment, cells were washed twice with PBS. Fixation solution was 
added (2% formaldehyde and 0.2% glutaraldehyde in PBS buffer) and incubated at room 
temperature for 5 min. fixation solution was removed and cells were washed twice with 
PBS. Staining was performed (40 mM citric acid/Na phosphate buffer, 5 mM 
K4[Fe(CN)6] 3H2O, 5 mM K3[Fe(CN)6], 150 mM sodium chloride, 2mM magnesium 
chloride and 1 mg/ml X-gal) and cells were incubated for 16 hrs at 37°C incubator.  By 
the end of incubation period, staining solution was removed and cells were washed twice 
with PBS and once with methanol, plate was left for air dry. Photomicrographs were 
taken from random fields and positive β-gal cells were counted and represented senescent 
cells. 
5) VSMC Hypertrophy: 
8000 VSMCs were seeded in 6-well plate and the next day, they were serum-
starved for 24 hrs. Cells were treated with CdCl2 as the following: control, 10 and 1000 
nM. Photos were taken for each treatment after 48. Cell areas were measured by using 
xyz software (IX71 Olympus).  
6) VSMC Viability: 
300 VSMCs cells were seeded in 96-well plate to reach 20-30% confluence in the 
next day. The plate was designed to study the concentration and time effect. When the 
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cells reached 20-30% media was changed to quiescent for 24 hrs. A wide range of CdCl2 
concentration was used: control, 10, 50, 100, 500, 1000 and 2000 nM. Each treatment has 
three replicates. The time duration was 24, 48 and 72 hrs. Then cells viability was 
determined using CellTiter-Glo Luminescent Assay (Promega; U.S) and following 
manufacturer protocol. First, plate was equilibrated at room temperature for 30 min. 
Second, 50 µl of CellTiter-Glo® Reagent (CellTiter-Glo® Buffer/Substrate mixture 
supplied with the kit) was added to each well, and the contents were mixed for 2 min on 
an orbital shaker to induce cell lysis. Then plate was incubated at room temperature for 
10 min to stabilize the luminescent signal. Finally, luminescence was recorded by using 
Luminometer (Promega; U.S). 
7) In vivo: Wistar Rat  
Male Wistar rat (N=40) were purchased from Charles River (UK) weighing 200-
250g. All experiments were conducted in accordance with the Guide for the Care and Use 
of Laboratory Animals and were approved by Qatar University Institutional Animal Care 
and Use Committee (QU-IACUC 010/2013). Rats were housed in a controlled lab 
conditions with a room temperature (18-25ºC), humidity (30-70%) and light cycle (12:12 
h light-dark). Rats were grouped into two groups. Control group (N=15) received filtered 
tap water as drinking water, whereas the Cd-treated group (N=25) were received filtered 
tap water containing CdCl2 (15mg/kg of body weight/day) continuously for eight weeks 
and fed with standard animal diet. All animals have free access to food and water. Food 
consumption, water intake and body weight gain were measured weekly. 
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8) Blood Pressure Measurements: 
Systolic (SBP), Diastolic Blood Pressure (DBP), Heart Rate (HR) and Mean 
Arterial Pressure (MAP) were measured using the CODA tail-cuff blood pressure system 
(Kent scientific Corporation; USA). Rats were picked randomly restrained in the rat 
holder and placed in a worming pad. The occlusion cuff placed close to the base of the 
tail, while the Volume Pressure Recording (VPR) cuff placed 2mm away from the 
occlusion cuff. The rat allowed to be thermoregulated. The temperature was recorded by 
infrared thermometer, which should be between 32-35°C. Five cycles were set as an 
acclimation cycles and fifteen as a regular cycles.  
9) Mesenteric arteries isolation: 
Rats were placed in CO2 chamber and euthanized by gradual release of CO2 from 
compressed CO2 cylinder. Immediately after euthanasia the rat was dissected and the 
mesentery was isolated and placed directly in a cold Physiological Salt Solution (PSS) 
(112mM NaCl, 5mM KCl,1.8mM CaCl2, 1mM MgCl2, 25mM NaHCO3, 0.5mM 
KH2PO4, 0.5mM NaH2PO4, 10mM Glucose). Under stereomicroscope (Olympus SZ61). 
The small mesenteric arteries were isolated, cleaned from fats, and placed in cold PSS 
solution. 
10) Vascular Reactivity: 
Two segments of small mesenteric arteries (one from control and one from 
treated) were mounted on two separate mounting jaws in one chamber of! an isometric 
myograph (model 510A, DMT, Denmark) containing 10 ml of PSS solution. The vessels 
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were maintained at 37°C and continuously aerated with a mixture of 95% O2+ 5% CO2. 
Vessel segments were then normalized by pre-tensioned to an equivalent of 100 mmHg 
using an in-built automatic normalization procedure. Normalization procedure is 
important step to determine the inner diameter of each artery. Vessels were equilibrated 
for a period of one hour between the mounting and experiment. During this period, 
90mM of KCl (once) and 10 µM phenylephrine (twice) were applied to test for viability 
and optimize the vessels for the experiment. In order to test the endothelial function, 
acetylcholine (10 µM) was applied after the second phenylephrine to relax the vessel. 
Once the equilibration period was done, a dose response test was performed for a 
serial concentration of phenylephrine (1-30000 nM) followed by!a washing period of 30 
min. after that, another test was carried out for the norepinephrine (1-30000 nM). 
Norepinephrine was then repeated in the presence of prazosin (3x10-7M), which was 
applied 30 min before norepinephrine. Prazosin is a selective α1 AR antagonist.  
11) Statistical analysis:  
Graphpad prisem software was applied for data analysis. In vitro data were 
analyzed using one-way ANOVA, while in vivo data were analyzed using two-way 
ANOVA. All data were applied to Fisher’s LSD test for multi-comparison. Additionally, 
the 50% effective concentrations (EC50) for each single concentration of agonist was 
determined using non-linear regression. Data are presented as mean standard error. A 
value of P<0.05 was considered statistically significant.  
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CHAPTER 3: RESEARCH RESULTS 
PART I: IN VITRO STUDIES 
#
A. Effect of cadmium on the expression of vascular α1 AR 
Cadmium induces the expression of α1 AR: 
To investigate if Cd could evoke α1 AR expression, Cells were treated with low 
serial concentration for varying durations. Results showed an increase in the expression 
of α1 AR in a concentration (Fig.5) and time (Fig.6) dependent manner. α1 AR 
significantly evoked when cells were treated with 500  and 1000nM CdCl2. This 
increment was 4 and 5 fold-increase for 500 and 1000nM respectively.  
(a) 
 
 
    
(b) 
 
Figure 5: Effect of CdCl2 on α1 AR 
expression.  HASMCs were treated with a 
serial concentration of CdCl2: 10, 100, 500 
and 1000nM for 48 hrs. (a) Expression of 
α1 AR compared to GAPDH. (b) 
Quantitative measure of α1 AR normalized 
with GAPDH. Data are presented as mean 
± SEM. *P < 0.05, **P < 0.01. n=3. 
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(a) 
!!!
       (b)! !!!!!
Figure 6: Expression of α1 AR over 
time. HASMCs were treated with 
1000nM CdCl2 for varying durations: 
24, 48 and 72 hrs. (a) Expression of α1 
AR over time. (b) Quantitative 
measures for α1 AR expression 
normalized with GAPDH. Data are 
presented as mean ± SEM. n=3. 
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Transcriptional activity and involvement of Protein Kinase A (PKA) pathway: 
To determine if the up-regulation of α1 AR is due to activation of transcription, 
cells were pretreated with actinomycin D to suppress DNA-dependent RNA synthesis. As 
previously shown, 1000nM CdCl2 significantly increases α1 AR expression. Here we 
show that this expression is abolished by actinomycin D pre-treatment (Fig. 7). To 
investigate if the expression of α1 AR is mediated by protein kinase A (PKA) pathway, 
Cells were pre-incubated with H89, a PKA inhibitor. The expression was abolished with 
H89 (Fig.8).   
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Figure 7: Transcriptional activity of α1 
AR. HASMCs were pretreated with 
5µg/ml actinomycin D (DNA-dependent 
RNA synthesis inhibitor) for 1 hr 
followed by CdCl2 treatment. Treatment 
was performed for 48 hrs. Data are 
presented as mean ± SEM. *Control vs 
1000nM. P < 0.05. n=3. 
 
Figure 8: PKA mediate α1 AR 
transcription. HASMCs were pretreated 
with 5mM H89 (PKA inhibitor) for 1 hr 
followed by CdCl2 treatment. Treatment 
was performed for 48 hrs. Data are 
presented as mean ± SEM. *Control vs 
1000nM. P < 0.05. n=3. 
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B. Effect of Cadmium on Vascular Smooth Muscle Cells (VSMCs) Phenotypic 
Modulation  !
VSMCs Hypertrophy: 
To determine the effect of Cd on VSMCs hypertrophy, Cells were treated with 10 
and 1000 nM CdCl2 for 48hrs. At 1000 nM cells showed to have a significant increase in 
cell area compared to control (fig.9). 
(a) ! 
 
 
 
 
 
 
 
 
 
 
Figure 9: VSMCs hypertrophy.  
HASMCs were treated with 10 
and 1000nM of CdCl2 for 48 hrs 
and cell area measured using xyz 
software (a). Control (b), 10nM 
(c), 1000nM (d).*P < 0.05. n=3. 
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VSMCs Migration:  
 To investigate if Cd induces migration of VSMCs. Cells were treated with 10 and 
1000 nM CdCl2. Migration chamber assay showed an increase in VSMCs migration in 
the presence of CdCl2. This increment showed to be significant at 1000nM (fig.10). 
Wound healing assay showed a faster healing in the presence of CdCl2 compared to 
control (fig.11).  
 ! !
               Control                                                   10nM                                                1000nM 
(a) 
(b) 
Figure 10: VSMCs migration chamber 
assay. HASMCs were treated with 10 and 
1000nM CdCl2 for 24 hrs. (a) high 
number of migratory cells stained with 
crystal violet showed at 1000nM. (b) 
Migration increased significantly at 
1000nM. Data are reported as mean ± 
SEM *P < 0.05. n=3. 
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VSMCs Senescence: 
To further test the role of Cd in VSMCs phenotypic changes and promote 
senescence, cells were treated with 10 and 1000 nM CdCl2 for 48 hrs and measured SA-
β-gal activity, a senescence marker. Senescence determined by counting SA-β-gal 
positive cells. Senescence was increased when cells incubated with CdCl2 and showed to 
be significant at 1000nM compared to control (fig.12).  
!
 
 
 
       Control                  10nM                  1000nM 
0hr 
24hrs 
Figure 11: Wound-healing assay. Qualitative results showed faster healing in HASMCs at 24 hrs for 
the wound created at 0 hrs. 
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Figure 12: VSMCs Senescence. (a) SA-β-gal positive cells increased with CdCl2 treatment, (b) significant at 1000nM 
after 48 hrs. Data are reported as mean ± SEM. *P < 0.05. n=3. 
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VSMCs Viability: 
 In order to detect the effect of Cd toxicity on the viability of VSMCs, 300 cells 
HASMCs were seeded in 24-well plates to get 20-30% confluent. Cells were treated with 
a wide range of CdCl2: 0, 10, 50, 100, 500, 1000 and 2000 nM for varying time. No effect 
was shown in cell viability between control and Cd treatment after 24 and 48 hrs 
incubation (fig.13, a and b). While after 72 hrs a decrease in viability was observed at!
2000 nM (fig.13, c).!!
  (a)                                                                   (b) !!! !!
Figure 13: VSMCs viability test: Effect of 
Cd treatment on cell viability after 24 hrs 
(a), 48 hrs (b) and 72 hrs (c). Data are 
reported as mean ± SEM *P < 0.05. n=3. 
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PART I: IN VIVO STUDIES!
A. Effect of Cadmium on the Sensitivity of Vascular α1 AR 
 Food intake and Body weight: 
In the present study, the daily food intake was   measured weekly during the entire 
period of the experiment, calculated, and expressed as amount of consumed food in 
grams/animal/day. The results did not show any significant difference between control 
and Cd-treated groups (fig.14, a) and (Table.4). The body weight was dramatically 
increased in both groups during the experiment as a part of normal age related growth, 
however no significant differences were observed between the two groups (fig.14, b) and 
(Table.5). ! Water Intake: the daily water consumption per animal was measured during the 
entire experiment and expressed as ingested amount of water in ml/animal/day. The 
results showed a highly significant decrease in the daily water consumption starting from 
the first day till the end of the experiment by the Cd-treated group compared to the 
control group (fig.14, c) and (Table.6).   
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Figure 14: The effects of Cd exposure on: Food intake (a). Body weight (b). Water intake 
(c). Values are means ± SEM.  **P<0.01, ***P=0.0001, ****P<0.0001. 
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Table 4: Food intake Means ± SEM (gm/rat/day). 
Weeks Control (n=8) Cd-Treated (n=16) 
Week 1 45.78 ± 4.15 46.81 ± 1.6 
Week 2 50.65 ± 4.39 46.18 ± 1.13 
Week 3 50.86 ± 3.75 48.00 ± 1.82 
Week 4 50.40 ± 5.09 46.10 ± 1.12 
Week 5 57.18 ± 8.05 50.42 ± 3.62 
Week 6 49.68 ± 3.3 49.16 ± 2.49 
Week 7 48.45 ± 3.02  50.96 ± 5.58 
Week8 47.11 ± 3.47 41.16 ± 2.28 
  
 
 
Table 5: Rats Body weight Means ± SEM (gm). 
Weeks Control (n=8) Cd-Treated (n=16) 
Baseline 297.01 ± 3.63 300.36 ± 3.8 
Week 1 338.41 ± 6.5 334.06 ± 4.9 
Week 2 375.36 ± 7.6 360.87 ± 5.7 
Week 3 395.17 ± 6.4 390.08 ± 5.2 
Week 4 432.52 ± 6.1 428.31 ± 5.8 
Week 5 455.17 ± 7.1 446.95 ± 5.9 
Week 6 475.77 ± 7.5 462.84 ± 6.6 
Week 7 496.03 ± 7.5 483.52 ± 6.8 
Week 8 512.27 ± 7.04 494.56 ± 6.4 
 
 
Table 6: Water intake Means  ± SEM (ml/rat/day). 
  
Weeks Control (n=8) Cd-Treated (n=16) 
Week 1 53.48 ± 3.8 43.14 ± 1.38  
Week 2 56.02 ± 2.03 40.95 ± 1.98 
Week 3 61.53 ± 2.12 38.85 ± 2.3 
Week 4 58.73 ± 2.86 38.42 ± 1.92 
Week 5 65.04 ± 6.17 38.19 ± 2.45 
Week 6 51.17 ± 1.6 32.56 ± 1.71 
Week 7 54.07 ± 3.3 30.56 ± 1.69 
Week8 57.10 ± 4.16 26.95 ± 1.02 
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 Blood Pressure: 
To determine the effect of Cd on blood pressure four parameters were measured 
immediately before the start of the experiment (baseline) and after 30 days: Systolic 
Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Heart Rate (HR) and Mean 
Arterial Blood Pressure (MAP). The results indicated that there was a slight non-
significant increase in the SBP baseline value (160.5 ± 3.2) of the control compared to 
the second group that was assigned for Cd treatment (151.8 ± 2.6) (Table.7). No 
differences in SBP were observed between control (160.7 ± 4.5) and treated (154.3 ± 3.3) 
after 30 days of Cd administration (Table.7). Cd did not affect DBP as shown in treated 
group (108.7 ± 3.15) compared to control (120.3 ± 3.4) (Table.8). Similar results were 
obtained from MAP (Table.9). Heart rate showed a slight increase in the baseline of 
control (480.7 ± 15.4) compared to treated (459.3 ± 26.3); yet this change was not 
significantly different (Table.10). No significant change in the HR was also observed 
between control (450.4 ± 19.1) and treated (448.04 ± 9.05) 30 days post-treatment. 
 
Table 7: Systolic blood pressure (mmHg) baseline and at 30 days of treatment. Mean ± SEM and % change. 
  Control (n=8) Cd-Treated (n=16) 
Baseline 160.5 ± 3.2 151.8 ± 2.6 
30 days  
post-Cd-
treatment 
160.7 ± 4.5 154.3 ± 3.3 
% Change 0.13 % 1.6 % 
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Table 8: Diastolic blood pressure (mmHg) baseline and at 30 days of treatment. Mean ± SEM and % change. 
 Control (n=8) Treated (n=16) 
Baseline 121.5 ± 2.3  109.6 ± 3.16 
30 days  
post-treatment 
120.3 ± 3.4 108.7 ± 3.15 
% Change 1.04 % 0.84 % 
 !
Table 9: Mean arterial blood pressure (mmHg) baseline and at 30 days of treatment. Mean ± SEM and % change. 
 
 
Table 10: Heart rate (bpm) baseline and at 30 days of treatment. Mean ± SEM and % change. 
 
 
 Control (n=8) Treated (n=16) 
Baseline 134.2 ± 2.5  123.38 ± 2.9 
30 days  
post-treatment 
133.4 ± 3.7 123.59 ± 3.2 
% Change 0.61 % 0.16 % 
 Control (n=8) Treated (n=16) 
Baseline 480.7 ± 15.4  459.3 ± 26.3 
30 days  
post-treatment 
450.4 ± 19.1 448.04 ± 9.05 
% Change 6.3 % 2.4 % 
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Vascular Reactivity: 
The effect of Cd on the contraction of mesenteric arteries in response to NE (ARs 
agonist) and phenylephrine (selective α1 AR agonist) was studied to determine the 
vascular α1 AR sensitivity. In response to phenylephrine, the results showed that there 
was a slightly shift to the left for the treated group after 30 days of Cd treatment (-5.442 ± 
0.139), which was not significantly differ from the control (-5.358 ± 0.067) (fig.15, a). In 
contrast, no shift at all was observed after 60 days (fig.15, b). The 50% effective 
concentrations for both groups were similar (Table.7). By conducting time-dependent 
comparison between control group and treated group in response to phenylephrine, both 
control and treated groups 60 days post-treatment revealed an enhancement in the trend, 
but this enhancement was not statistically different (fig.15, c and d) (EC50 values showed 
in Table.7). 
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Figure 15: The effect of Cd exposure on concentration response curve to phenylephrine: 
control vs Cd-treated 30 days post-treatment (a), control vs Cd-treated 60 days post-
treatment (b), control 30 days post-treatment vs control 60 days post-treatment (c), Cd-
treated 30 days post-treatment vs Cd-treated 60 days post-treatment (d) Values are means 
± SEM.  **P<0.01. 
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Table 11: The 50% effective concentrations (EC50) for control and Cd-treated in response to phenylephrine, 30 days 
and 60 days post-treatment. 
 
In Cd-treated group, the contractile response induced by NE was increased in rat 
mesenteric artery (-5.358 ± 0.119) compared to control (-5.224 ± 0.096) 30 days post-
treatment, but this increment was not significantly different (fig.16, a). No effect of Cd 
was shown 60 days post-treatment (EC50 values showed in Table.5) (fig.16, b). In time 
dependent comparison, both curves (control and treated) were augmented in response to 
NE 60 days post-treatment and showed a significant increase at dose 10-5.5 M.L-1 (fig.16, 
c and d). The EC50 values were -5.673 ± 0.023 and -5.589 ± 0.041 for control and treated 
respectively 60 days post-treatment (Table.5). 
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Duration Control Cd-treated 
30 days post-treatment -5.358 ± 0.067 -5.442 ± 0.139 
60 days post-treatment -5.579 ± 0.167 -5.549 ± 0.086 
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Figure 16: The effect of Cd exposure on concentration response curve to 
Norepinephrine (NE): control vs Cd-treated 30 days post-treatment (a), control vs 
Cd-treated 60 days post-treatment (b), control 30 days post-treatment vs control 60 
days post-treatment (c), Cd-treated 30 days post-treatment vs Cd-treated 60 days 
post-treatment (d) Values are means ± SEM.  **P<0.01. 
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Table 12: The 50% effective concentrations (EC50) for control and Cd-treated in response to norepinephrine (NE), 30 
days and 60 days post-treatment. 
 
To determine the effect of Cd on other alphas receptors such as α2 AR, mesenteric 
arteries were pre-treated with Prazosin (selective α1 AR antagonist). The response was 
diminished in both groups in response to NE after 30 and 60 days of treatment (fig.17).  
 
  
 
 
 
 Control Cd-treated 
30 days post-treatment -5.224 ± 0.096 -5.358 ± 0.119  
60 days post-treatment -5.673 ± 0.023 -5.589 ± 0.041 
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Figure 17: Vascular response to norepinephrine (NE) in presence of α1 AR antagonist (prazosin, 30min before 
NE). (a) 30 days post-treatment. (b) 60 days post-treatment. 
 
(a) 
(b) 
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CHAPTER 4: DISCUSSION  
Cardiovascular diseases (CVDs) are one of the main causes of death worldwide. 
Several risk factors contribute to the etiology of CVDs such as tobacco smoke, 
hyperlipidemia, atherosclerosis, hypertension and environmental pollution. Cadmium 
(Cd) is one of the most harmful environmental pollutants and has been associated with 
high blood pressure. Although many pathways have been tested to explain Cd 
contribution to hypertension, little is known about the involvement of α1 AR and 
phenotypic modulation of VSMCs. In our study we investigated the possible role of the 
α1 AR receptors and phenotypic modulation of VSMCs as a key players in hypertension. 
Alpha ARs are highly distributed among the vascular tree of the human body. α1 
AR is mostly expressed in the VSMCs compared to other cell types. Due to its presence 
in the VSMCs, α1 AR is the major regulator of the vascular tone. High expression of α1 
AR is positively correlated with the pathogenesis of CVDs. As we mentioned above, Cd 
is a dangerous pollutant revealed to be a contributor in the elevation of blood pressure.  
In this report, our results showed that Cd significantly increased the expression of 
α1 AR in concentration and time dependent manner. This suggests that α1 AR could be 
one of the mechanisms that mediate Cd-induced hypertension. Physiologically, α1 AR is 
activated through EP or NE binding to induce contraction. EP and NE are locally 
regulated via an enzyme called Catechol-O-methyltransferase enzyme (COMT). This 
enzyme has been showed to be inhibited due to Cd toxicity leading to an increase in the 
serum and urine level of EP and NE (101). Cd also appears to augment the vascular 
responses to NE (106).  Taken together, this means that by inactivating COMT and thus 
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increasing catecholamine levels in the blood, Cd may be increasing the pressor responses 
to EP. As we show here, Cd also increased the expression of α1 AR. This could be one 
underlying mechanism by which Cd potentiated the VSMC contraction. However, further 
experiments are warranted before such a conclusion can be made.  
Gene expression can be controlled via transcription regulation, or post-
transcriptional regulation. Here, we show that the α1 AR -induced expression is due to a 
transcriptional activation, evident by the absence of induction when cells were pretreated 
with actinomycin D, a DNA-dependent RNA synthesis inhibitor. Transcriptional 
regulation of α1 AR could be modulated by several parameters such as: hypoxia, ischemic 
reperfusion, growth factors, cyclic adenosine monophosphate (cAMP) and catecholamine 
stimulation (27). Catecholamines, of which NE is one, induces the m-RNA level of α1 AR 
under chronic stimulation in the neonatal rat cardiomyocytes (108). The regulation of 
transcriptional action is initiated through intracellular signal transduction such the cAMP-
PKA pathway. Interestingly, we found that the observed significant increase of α1 AR 
expression was abolished in the presence of H89, a PKA inhibitor. This suggests that 
transcriptional activity of α1 AR was mediated via the PKA pathway. Once PKA is 
activated by cAMP, PKA is translocated to the nucleus where it activates cAMP response 
element-binding protein (CREB). CREB is a transcription factor that binds to DNA and 
can act to switch on the gene expression of α1 AR. Evidence indicates that activation of α1 
AR could increase cAMP level in some cells (109). Other evidence indicates that α1 AR 
stimulation leads to the phosphorylation of CREB (27). Taken together, it is possible that 
Cd induce the α1 AR expression through the stimulation of α1 AR, which increases the 
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cAMP level (109), inside the VSMC leading to the activation of PKA as we showed in 
our results. Finally PKA activation stimulates the CREB phosphorylation (27), to switch 
on the α1 AR transcription and m-RNA production. This positive feedback regulation in 
response to Cd toxicity could explain how relatively very small amount of Cd precipitates 
various diseases, particularly hypertension. However, further experimentation is 
warranted in order to validate this apparently vicious signaling loop.  
The excited findings from the in vitro work were applied to further investigation 
by in vivo studies. Wistar rat was our normotensive model in this study because it is the 
most commonly used rat model in CVDs research. Food intake, body weight and water 
intake were monitored in order to determine the effect of Cd on the normal metabolic 
parameters. Our results revealed that Cd has no direct effect on food intake and body 
weight of the rats. However, a high significant decrease in water intake was observed in 
the Cd-treated rats compared to control, which could be due to the water taste. This 
significant reduction in water consumption of the Cd-treated group did not influence the 
body weight gain; this could be due to the observed increase in the amount of visceral fat. 
Functional studies were applied to investigate the vascular α1 AR sensitivity under Cd 
treatment, using phenylephrine and NE, selective and non-selective α1 AR agonists.  We 
found that vascular reactivity was slightly affected. Cd shifted the phenylephrine 
concentration-response curve to the left (not statistically significant) in the mesenteric 
arteries isolated from Cd-treated rats after 30 days of treatment. However, Cd didn’t 
show any enhancement after 60 days treatment. Further investigations were conducted in 
order to examine the effect of NE on Cd-induced vascular α1 AR activity. The results 
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were similar to phenylephrine response after 30 and 60 days. Conflicting findings were 
reported recently by Almenara et al. (2013), who reported a greater increase of the 
contraction response to phenylephrine in the aortic rings of Cd-treated rat (100mg.L-1) for 
4 weeks (50), which represent 30 days in our study. The conflict of results could be 
explained by the response effect occurs after 30 days but not 60 days may be due to the 
long period of Cd exposure in relevance to the accumulative dose that may suppresses the 
sensitivity of the α1 AR. This explanation can be supported by finding reported by 
Skoczyńska (1997) about the potentiation vasoconstriction effect of NE on isolated rat 
mesenteric artery treated with 2.85 mg/kg/day (106). The type of tested vessels could 
contribute to the difference in the response between our result and the result of Almenara 
et al. Ordinarily, due to the size differences between aorta and mesenteric arteries, aorta 
exhibits more force than mesenteric artery and even the expression of α1 AR may be 
higher in the aorta. Additionally, we were also compared between the control groups and 
treated groups to see the time-dependent differences between them. A shift to the left was 
observed in both control and treated groups after 60 days of treatment comparing to 30, in 
response to phenylephrine. While in response to NE higher augmentation was resulted 
and showed to be significant at dose 10-5.5 M.L-1 . These findings could be an age-related 
factor due to the increase in animal age. Increase in blood pressure is highly expected in 
aged people. It has been reported that aging is associated with the elevation in plasma 
catecholamines level (110), as well as α1 AR expression (111). Beside the α1 AR role in 
VSMCs contraction, we were interested to look at role of other type of alpha ARs such as 
α2 AR. This was examined by blocking the α1 AR with its antagonist prazosin. The 
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response curve to NE was diminished after blocking the α1 AR. This means α2 AR has no 
role in mediating VSMCs contraction under Cd toxicity.  
The present study did not show any significant change in values of SBP, DBP, 
HR or MAP between control and Cd-treated. The vascular reactivity data support these 
results, whereas other conflicting data reported that Cd significantly increased the SBP, 
DBP and the MAP of mice treated with 100 mg/l CdCl2 via drinking water for 8 weeks 
(24). This could be related to the species of the animal and Cd dose. Here we used rat 
instead of mice, and higher Cd dose compared to 100mg/l. 
This apparent contradiction in our data between the in vitro (α1 AR expression) 
and in vivo (α1 AR activity) could be related to various factors. Species differences 
between the two models may be one of them. In the in vitro we used the human primary 
cell line (HASMCs) where rats were used as a model for the in vivo. Thus, Cd may 
induce the expression of α1 AR in human cells but not in rat tissues. Moreover, in vivo 
where more physiological exist other parameter may influence or modulate the effect 
rather than the in vitro setting. In the in vitro Cd target the VSMCs directly, where in the 
in vivo Cd crosses different barriers to reach the VSMCs. 
Phenotypic modulation of VSMCs is a normal physiological function in response 
to vessel damage. Under certain pathologic conditions, phenotypic modulation could 
have an important role in narrowing the blood vessel, which would then drastically 
impact blood pressure. Our study aimed also to study the effect of Cd on the VSMCs 
phenotypic modulation as a factor of vascular pathogenesis underlying hypertension. 
Hypertrophy (increase in cell area), and hyperplasia (increase in cell volume) are critical 
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in narrowing blood vessel. Our results illustrated that Cd prompt the hypertrophy of 
HASMCs as it was shown in the significant increase of cell area at 1000nM Cd treatment. 
Along with these findings, Mikhaleva et al. (1991) found that chronic Cd exposure in rats 
causes hypertrophic effects in the arterial wall as well as the left ventricular 
cardiomycetes (86). From the viability test, Cd didn’t show any signs of cell proliferation, 
which result in hyperplasia. In contrast, Cd has been reported to increase cell 
proliferation at 100nM or less in bovine and rabbit aortic smooth muscle cells (92). This 
could be related to species differences.   
VSMCs migration was studied, which is a well-known phenomenon of 
atherosclerosis. In the present study, results revealed that Cd induces HASMCs 
migration, which is a main contributor in the formation of the neointima. Normally, the 
formation of neointima started by ECs injury or dysfunction. As a result, injured ECs 
express adhesion molecules such as: ICAM-1 and VCAM-1 to facilitate the migration of 
monocyte to reach the intima. Once these monocytes arrive to the intima, they start to 
secret inflammatory cytokines and growth factors to stimulate VSMCs migration from 
the medial layer to the intima, where they would proliferate forming neointima. Under Cd 
toxicity, the number of leukocytes increased significantly in Cd-treated mice (88). In 
addition, Cd showed to induce the expression of adhesion molecules (ICAM-1) and 
(VCAM-1) (87) and the secretion of inflammatory cytokines (89), (90). Additionally, the 
disruption of the extracellular matrix is one of the key players in VSMCs migration. 
Matrix metalloproteinases (MMPs) are enzymes that have a role in this action. They 
catalyze the connective tissues and extracellular matrix to induce migration. Indeed, 
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MMPs expression showed to be elevated in Cd-treated rat (93). Moreover, the cellular 
signal transduction that mediates VSMCs migration needs to be verified. An evidence 
showed that extracellular signal-regulated kinases (ERK1/2) were involved in VSMCs 
migration after pre-treatment with AngII (112). Equally important, CdCl2 reported to 
increase ERK1/2 in a biphasic manner in SHR VSMCs. Furthermore, Cd showed to 
induce the phosphorylation of ERK1/2 in pancreatic b-Cells (113). This suggests that Cd 
stimulates VSMCs migration via ERK1/2 signaling pathway.  
Vascular senescence is another type of vascular remodeling that occurs normally 
in aged people. Due to its health impact on vascular pathogenesis and hypertension, our 
findings showed that Cd promotes HASMCs senescence in a concentration dependent 
manner. Senescent VSMCs are commonly found in atherosclerotic plaque (33). The 
presence of senescent cells in atherosclerotic plaque may affect the stability of the plaque 
and leads to a serious complication of atherosclerosis, which is the plaque rupture. 
Indeed, senescence can also induced via cellular stress such as oxidative stress (33). 
Vascular senescence can be recognized by a number of markers. These markers include: 
increase in ROS production, positive to β-galactosidase activity and expression of cell 
cycle arrest proteins. Supportive evidence showed that Cd induces oxidative stress and 
the generation of free radicals and reactive oxygen species (59), (60). It has been revealed 
that Cd increased the generation of intracellular ROS in pancreatic b-Cells and the 
phosphorylation of p38 protein as a sign of cell cycle arrest (113). This suggests that Cd 
induces ROS production, which may then activate signal transduction resulting in p38 
phosphorylation leading to inhibition of cell growth. More investigations are needed, 
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however, to clarify the mechanism of Cd-induced VSMCs senescence.  
Generally, phenotypic modulation can be triggered due to various factors and 
stimuli. During this process, VSMCs phenotype shifted from contractile phenotype to a 
synthetic phenotype. This shift is characterized by changes in gene expression. In this 
regard, these changes include silencing of contractile gene expression and up-regulation 
of other functional genes that are responsible to stimulate synthetic phenotype such as: 
migration, cell proliferation, hypertrophy and senescence. Therefore, gene expression can 
be suggested as a future target of therapeutic approach in Cd-induced vascular phenotypic 
modulation. One of the suggested directions is using the micro-RNAs (miRNAs), which 
is a critical regulator of gene expression (114). Another factor can be involved in the 
initiation of VSMCs phenotypic modulation, which is the destruction of cell surface 
heparan sulfate. Heparan sulfate is a glycoprotein present on the cell membrane and has a 
role in the organization of actin filaments and stabilization of cell morphology. Thus, 
degradation of cell surface heparan sulfate may induce VSMCs phenotype by affecting 
actin organization and activation of gene expression (115). Hence, Cd-induced 
phenotypic modulation is critical and plays a role in vascular pathogenesis including 
hypertension (our focus in this study). It needs more attention and complete 
understanding of the underlying mechanisms that initiate it. To our knowledge, our 
findings regarding the effects of Cd on HASMCs phenotypic modulation have never been 
addressed before, so we are the first in reporting descriptive findings on HASMCs 
phenotypic modulation. The underlying mechanisms that mediate HASMCs phenotypic 
modulation are our future direction in order to have a clear and solid image.    
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The interpretation of these results direct us to consider some limitations. The 
number of mesenteric arteries used in the vascular reactivity experiment could be one of 
the most important limitations. As shown in the results, both response curves 
(phenylephrine and norepinephrine) were shifted to the left, but the difference was not 
statistically different. Therefore, number of animals could be a factor at the 30 days tested 
time, where if the number increased this could enhance the response curve more than 
what we obtained. This could be reflected from our capabilities in having a team that can 
help in the in vivo part, which needs extra time and efforts. Beside the limitations, the 
strength of our study can be shown from the combination between two fields, which are 
the in vitro and in vivo to help in presenting the complete picture. Excitingly, we are the 
first who report the direct effect of Cd on the expression of α1 AR and the signaling 
pathway that mediate this expression, as well as the phenotypic modulation of HASMCs. 
To our knowledge, no one has reported these findings before.  
 !  
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CHAPTER 5: CONCLUSION 
In conclusion, our results dissect a novel pathway employed by cadmium to 
increase expression of vascular α1 AR a major player in hypertension, via transcriptional-
dependent mechanism. Moreover, this expression of α1 AR was diminished when cells 
were pre-incubated with H89, a protein kinase A (PKA) inhibitor. This indicates that 
PKA plays an important role in mediating the Cd-induced expression of α1 AR. 
Functional studies did not show any significant effect on vascular reactivity in response 
to α1 AR agonists as well as blood pressure.  In addition Cd showed to be highly involved 
in VSMCs phenotypic modulation. It has induced hypertrophy, migration and 
senescence. These modulations associated with many CVDs including hypertension. This 
new paradigm offers a better understanding and thus potential improvement of pollution-
related CVDs. Subsequently, the findings of this study can be applied in Qatar due to 
high prevalence of CVDs among Qatari population, thus Cd could be one of the 
contribution risk factors in this health problem. Because Qatar is facing a rapid 
urbanization and increase in industrial activities especially in the last few years, more 
studies should be conducted to determine the level and the sources of Cd contamination. 
Future Directions 
This thesis formulated a comprehensive data on a proposed mechanism of Cd-
induced hypertension. Our work opens up some paths for future work in Cd toxicity and 
vascular diseases including hypertension. We suggest that Cd induce the expression of α1 
AR as a blood pressure modulator, however the expression of each subtype of α1 AR 
needs to be investigated. Here we agreed that Cd up-regulate the α1 AR expression, but 
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the functional activity of the receptor was not tested in vitro. This can be easily tested by 
treating the HASMCs with 1000nM CdCl2 for 48 hrs and then examine the cells response 
to EP and NE. The reactivity can be recorded by video camera under inverted 
microscope. Results can be analyzed by using ImageJ software. α2 ARs are located pre-
synaptic at the nerve ends and have a role in the regulation of EP and NE secretion. The 
direct effect of Cd on the expression of α2 ARs is also an interesting point to elucidate.  
In the in vivo studies, we showed that the mesenteric artery intoxicated with 
15mg/kg/day did not significantly enhance the vascular activity, so we are interested in 
looking at the effect of Cd on the aorta responsiveness. It has been reported that Cd lead 
to endothelial damage and dysfunction (77), therefore vasodilation activity may have a 
role in modulating the vascular tone. More supportive studies on the vasodilation of the 
vascular bed under Cd toxicity can be addressed by looking at the expression of eNOS 
and bioavailability of NO. Histological studies also can help visualizing possible damage 
of the vascular wall that may result from Cd toxicity.  
In the present study, we reported the descriptive results of VSMCs phenotypic 
modulation. We showed that Cd induced VSMCs migration, hypertrophy and senescence. 
Whereas, the underlying mechanisms that mediates phenotypic modulation needs to be 
clarified. Different signaling pathways may be involved. It has been reported that the 3 
Mitogen Activated Protein (MAP) kinases such as; c-Jun NH2-terminal kinase (JNK), 
extracellular signal-regulated kinase (ERK), and p38 kinases had a role in VSMCs 
phenotypic modulation like migration, proliferation and gene expression (116). These 
MAP kinases are highly important to be validated to figure out the mechanisms of Cd-
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induced VSMCs phenotypic modulation. Investigating the underlying mechanisms of Cd-
induced phenotypic modulation will be significant for future therapeutic inventions.     
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